EMA Considers Whether Intrathecal Zolgensma Deserves Fast Tracking

 
• By Neena Brizmohun

Novartis is planning to file EU and US marketing applications for an intrathecal formulation of its spinal muscular atrophy gene therapy, Zolgensma, in H1 2025.

Preparation of patient before performing spinal anaesthesia or Lumbar puncture
An intrathecal formulation of Zolgensma has been developed for use in older patients (Shutterstock)

More from EU CHMP

More from Pathways & Standards